Distinguishing Alzheimer's disease from other major forms of dementia
- PMID: 22014137
- PMCID: PMC3225285
- DOI: 10.1586/ern.11.155
Distinguishing Alzheimer's disease from other major forms of dementia
Abstract
Alzheimer's disease (AD) is the most common and most studied cause of dementia. Significant advances have been made since the first set of clinical criteria for AD were put forth in 1984 that are now captured in the new criteria for AD published in 2011. Key features include recognition of a broad AD spectrum (from preclinical to mild cognitive impairment to AD dementia) and requirement of AD biomarkers for diagnosis. Correctly diagnosing dementia type is increasingly important in an era when potential disease-modifying agents are soon to be marketed. The typical AD dementia syndrome has at its core, an amnestic syndrome of the hippocampal type, followed by associated deficits in word-finding, spatial cognition, executive functions and neuropsychiatric changes. Atypical presentations of AD have also been identified that are presumed to have a different disease course. It can be difficult to distinguish between the various dementia syndromes given the overlap in many common clinical features across the dementias. The clinical difficulty in diagnosis may reflect the underlying pathology, as AD often co-occurs with other pathologies at autopsy, such as cerebrovascular disease or Lewy bodies. Neuropsychological evaluation has provided clinicians and researchers with profiles of cognitive strengths and weaknesses that help to define the dementias. There is yet no single behavioral marker that can reliably discriminate AD from the other dementias. The combined investigation of cognitive and neurobehavioral symptoms coupled with imaging markers could provide a more accurate approach for differentiating between AD and other major dementia syndromes in the future.
Similar articles
-
Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers.J Alzheimers Dis. 2018;61(2):761-772. doi: 10.3233/JAD-170650. J Alzheimers Dis. 2018. PMID: 29254091
-
Cognitive, Psychiatric, and Motor Symptoms-Based Algorithmic Approach to Differentiate Among Various Types of Dementia Syndromes.J Nerv Ment Dis. 2022 Feb 1;210(2):129-135. doi: 10.1097/NMD.0000000000001428. J Nerv Ment Dis. 2022. PMID: 35080518 Review.
-
FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.Neuroimage Clin. 2018 Jan 28;18:167-177. doi: 10.1016/j.nicl.2018.01.019. eCollection 2018. Neuroimage Clin. 2018. PMID: 29387532 Free PMC article.
-
Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.Int Psychogeriatr. 1997;9 Suppl 1:191-222; discussion 247-52. Int Psychogeriatr. 1997. Corrected and republished in: Int Psychogeriatr. 1998 Sep;10(3):271-302. doi: 10.1017/s1041610298005389. PMID: 9447442 Corrected and republished.
-
Patterns of cognitive impairment in Alzheimer's disease: assessment and differential diagnosis.Front Biosci. 2002 May 1;7:e155-84. doi: 10.2741/A914. Front Biosci. 2002. PMID: 11991855 Review.
Cited by
-
Does Cognitive Stimulation Therapy show similar efficacy in individuals with mild-to-moderate dementia from varying etiologies? An examination comparing its effectiveness in Alzheimer's disease and vascular dementia.Int J Clin Health Psychol. 2024 Oct-Dec;24(4):100510. doi: 10.1016/j.ijchp.2024.100510. Epub 2024 Oct 18. Int J Clin Health Psychol. 2024. PMID: 39474512 Free PMC article.
-
MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer's disease.BMC Neurosci. 2021 May 25;22(1):39. doi: 10.1186/s12868-021-00643-2. BMC Neurosci. 2021. PMID: 34034683 Free PMC article.
-
Lipid Droplets in Neurodegenerative Disorders.Front Neurosci. 2020 Jul 29;14:742. doi: 10.3389/fnins.2020.00742. eCollection 2020. Front Neurosci. 2020. PMID: 32848541 Free PMC article. Review.
-
Genetic effects and gene-by-education interactions on episodic memory performance and decline in an aging population.Soc Sci Med. 2021 Feb;271:112039. doi: 10.1016/j.socscimed.2018.11.019. Epub 2018 Nov 10. Soc Sci Med. 2021. PMID: 30449520 Free PMC article.
-
Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?Front Pharmacol. 2022 May 11;13:893422. doi: 10.3389/fphar.2022.893422. eCollection 2022. Front Pharmacol. 2022. PMID: 35645791 Free PMC article. Review.
References
-
- Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Trans. Suppl. 1988;53:127–140. [Seminal article that describes the spread of neuropathologic changes in Alzheimer's disease (AD).] - PubMed
-
- Salmon DP, Bondi MW. Neuropsychology of Alzheimer's disease. In: Terry RD, Katzman R, Bick L, Sisodia SS, editors. Alzheimer Disease. Lippincott Williams and Wilkens; Philadelphia, PA, USA: 1999. pp. 39–56.
-
- Mckhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944. - PubMed
-
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging – Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263–269. [Important article outlining the new criteria for AD dementia.] - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical